10219T

14/15

Ⅲ　章推　奨 2） Simon ST, Kloke M, Alt■Epping B, et al. EffenDys■fentanyl buccal tablet for the relief of epi-sodic breathlessness in patients with advanced cancer:a multicenter, open■label, randomized, morphine■controlled, crossover, phase Ⅱ trial. J Pain Symptom Manage 2016;52:617■25 3） Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage 2010;39:820■30 4） Navigante AH, Cerchietti LC, Castro MA, et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symp-tom Manage 2006;31:38■47 5） Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with 6） Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory func-tion in elderly patients with advanced cancer:a randomized double■blind controlled trial. Ann Oncol 1999;10:1511■4 7） Bruera E, MacEachern T, Ripamonti C, et al. Subcutaneous morphine for dyspnea in cancer 【文　献】 1） Yamaguchi T, Matsuda Y, Matsuoka H, et al. Efficacy of immediate■release oxycodone for dyspnoea in cancer patient:cancer dyspnoea relief（CDR）trial. Jpn J Clin Oncol 2018;48:1070■5cancer dyspnea:a preliminary study. J Pain Symptom Manage 2005;29:613■8patients. Ann Intern Med 1993;119:906■71352　がん患者の呼吸困難に対する薬物療法